These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 280161)

  • 1. Increased toxicity of 9-beta-D-arabinofuranosyladenine in the presence of an inhibitor of adenosine deaminase.
    Plunkett W; Cohen SS
    Ann N Y Acad Sci; 1977 Mar; 284():91-102. PubMed ID: 280161
    [No Abstract]   [Full Text] [Related]  

  • 2. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
    Plunkett W; Cohen SS
    Cancer Res; 1975 Jun; 35(6):1547-54. PubMed ID: 1079475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues.
    Plunkett W
    Ann N Y Acad Sci; 1985; 451():150-9. PubMed ID: 3907452
    [No Abstract]   [Full Text] [Related]  

  • 4. Toxicities of adenosine and 2'-deoxyadrenosine in L cells treated with inhibitors of adenosine deaminase.
    Lapi L; Cohen SS
    Biochem Pharmacol; 1977 Jan; 26(1):71-6. PubMed ID: 299815
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of adenosine deaminase by co-vidarabine and its effect on the metabolic disposition of adenine arabinoside (vidarabine).
    Borondy PE; Chang T; Maschewske E; Glazko AJ
    Ann N Y Acad Sci; 1977 Mar; 284():9-20. PubMed ID: 280160
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nornyl)adenine on plasma levels and urinary excretion of 9-beta-D-arabinofuranosyladenine in the mouse 1,2,3.
    Suling WJ; Rice LS; Shannon WM
    Cancer Treat Rep; 1978 Mar; 62(3):369-73. PubMed ID: 647695
    [No Abstract]   [Full Text] [Related]  

  • 7. Erythro-9-(2-hydroxy-3-nonyl) Adenine alone and in combination with 9-beta-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice.
    Shannon WM; Arnett G; Schabel FM; North TW; Cohen SS
    Antimicrob Agents Chemother; 1980 Oct; 18(4):598-603. PubMed ID: 6255863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a new adenosine deaminase inhibitor, isocoformycin, on toxicity, antitumor activity and tissue distribution of formycin A and 9-beta-D-arabinofuranosyladenine.
    Hidaka T; Katayama K; Yamashita K; Yamashita T; Watanabe K; Shimazaki M; Ohno M; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1980 Mar; 33(3):303-9. PubMed ID: 7380742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of 3'-deoxyadenosine N1-oxide and adenosine deaminase inhibitors on growth of Ehrlich ascites tumor cells in vivo.
    Svendsen KR; Overgaard-Hansen K; Frederiksen S
    Cancer Chemother Pharmacol; 1988; 21(1):35-9. PubMed ID: 3257721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of adenosine deaminase inhibitors on the apparent rate of phosphorylation of deoxyadenosine.
    Deibel MR; Coleman MS; Hutton JJ
    Biochem Med; 1981 Jun; 25(3):288-97. PubMed ID: 6973972
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo.
    Plunkett W; Alexander L; Chubb S; Loo TL
    Biochem Pharmacol; 1979; 28(2):201-6. PubMed ID: 426835
    [No Abstract]   [Full Text] [Related]  

  • 12. Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
    Cristalli G; Franchetti P; Grifantini M; Vittori S; Lupidi G; Riva F; Bordoni T; Geroni C; Verini MA
    J Med Chem; 1988 Feb; 31(2):390-3. PubMed ID: 3339608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of adenosine deaminase inhibitors.
    Henderson JF; Brox L; Zombor G; Hunting D; Lomax CA
    Biochem Pharmacol; 1977 Nov; 26(21):1967-72. PubMed ID: 562667
    [No Abstract]   [Full Text] [Related]  

  • 14. Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase.
    Plunkett W; Alexander L; Chubb S; Loo TL
    Cancer Res; 1979 Sep; 39(9):3655-60. PubMed ID: 476690
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of drug metabolism by a prodrug: 9-beta-D-arabinofuranosyladenine 5'-valerate as an inhibitor of adenosine deaminase.
    Lipper RA; Machkovech SM; Drach JC; Higuchi WI
    Mol Pharmacol; 1978 Mar; 14(2):366-9. PubMed ID: 642934
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on the effects of infusion of enzyme inhibitors on mouse adenosine deaminase.
    Trotta PP; Ahland MP; Brown GF; Balis ME
    Mol Pharmacol; 1978 Jan; 14(1):199-209. PubMed ID: 625284
    [No Abstract]   [Full Text] [Related]  

  • 17. Adenine arabinoside inhibition of adenovirus replication enhanced by an adenosine deaminase inhibitor.
    Wigand R
    J Med Virol; 1979; 4(1):59-65. PubMed ID: 119038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a novel adenosine deaminase inhibitor (co-vidarabine, co-V) upon the antiviral activity in vitro and in vivo of vidarabine (Vira-Atm) for DNA virus replication.
    Sloan BJ; Kielty JK; Miller FA
    Ann N Y Acad Sci; 1977 Mar; 284():60-80. PubMed ID: 212990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of cytotoxicity and antitumor activity of adenosine analogs by the adenosine deaminase inhibitor adecypenol.
    Tanaka H; Kawakami T; Yang ZB; Komiyama K; Omura S
    J Antibiot (Tokyo); 1989 Nov; 42(11):1722-4. PubMed ID: 2584153
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibitors of adenosine deaminase and the development of antiviral agents.
    Cohen SS
    Ann N Y Acad Sci; 1985; 451():204-14. PubMed ID: 2416257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.